Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins

Abstract

Background

Statin intolerance is a medical condition often leading patients to nonadherence to the prescribed therapy or to a relevant reduction of the statin dosage. Both situations determine a totally or partially uncontrolled lipid profile, and these conditions unquestionably increase the risk of cardiovascular events.

Methods

We enrolled hypercholesterolemic, type 2 diabetic patients complaining of intolerance to statins. Some of them had reduced the statin dose ‘until the disappearance of symptoms’; others had opted for treatment with ezetimibe; and yet others were not undergoing any treatment at all. All patients of the three groups were then given a fixed combination of berberine and silymarin (Berberol^®), known from previous papers to be able to control both lipidic and glycemic profiles.

Results

The tested product both as a single therapy and as add-on therapy to low-dose statin or to ezetimibe reduced triglycerides, low-density lipoprotein cholesterol, fasting blood glucose, and glycosylated hemoglobin in a significant manner without inducing toxicity conditions that might be somehow ascribed to a statin-intolerant condition.

Conclusion

Our study demonstrates that use of Berberol^®, administered as a single or add-on therapy in statin-intolerant subjects affected by diabetes and hypercholesterolemia is a safe and effective tool capable of improving the patients’ lipidic and glycemic profiles.

Keywords:

• berberine
• silymarin
• Berberol^®
• ezetimibe
• cholesterol
• type 2 diabetes

Acknowledgments

The authors wish to thank Dr Paolo Risso for the statistical analysis of the results.

Disclosure

FDP is the main formulator and patent sole inventor of Berberol^®. The other authors report no conflicts of interest in this work.